Understanding Imfinzi treatment for
your patients with extensive-stage small cell
lung cancer (ES-SCLC)
Please click the links above or the images below to download resources and view support materials to help manage patients taking Imfinzi.
About Imfinzi
Would you like to receive updated IMFINZI resources or
information on AstraZeneca Oncology products?
Be IN the know with Imfinzi's CASPIAN OS dataCASPIAN: Primary OS analysis
(full analysis set, median duration of follow-up 14.2 [11.7‒17.0] months [censored patients])1,2
27% relative reduction in instantaneous risk of death for Imfinzi + EP vs. EP alone1
HR: 0.73 (95% CI: 0.591, 0.909); p=0.00471
mOS: Imfinzi + EP vs. EP alone
13.0 months (95% CI: 11.5, 14.8) for Imfinzi + EP vs. 10.3 months (95% CI: 9.3, 11.2) for EP alone1
See study parameters below.†
CI, confidence interval; EP, etoposide and either carboplatin or cisplatin; HR, hazard ratio; mOS, median overall survival.
CASPIAN: 3-year updated OS analysis
(planned exploratory analysis, median duration of follow-up 39.4 [0.1‒47.5] months)3*
OS WITH Imfinzi + EP VS. EP ALONE3
See study parameters below.†
Adapted from Paz-Ares L. et al. 2022.3
CI, confidence interval; EP, etoposide and either carboplatin or cisplatin; HR, hazard ratio; mOS,
median overall survival.
*Not formally statistically tested.
Start with Imfinzi + EP in the first-line setting in your patients with ES-SCLC.
Click here to download the full study and learn more.
Planned exploratory analysis from the CASPIAN trial showed sustained OS benefit at 3 years consistent with the primary analysis.1-3 †
†CASPIAN was an open-label, phase III study in which patients with treatment-naïve ES-SCLC and World Health Organization performance status 0/1 were randomized 1:1 to Imfinzi 1,500 mg + etoposide (80‒100 mg/m2) on Days 1, 2, and 3 and either carboplatin (AUC 5 or 6 mg/mL/min) or cisplatin (75‒80 mg/m2) on Day 1 (EP), or EP. Patients in the immunotherapy arm received 4 cycles of EP + Imfinzi 1,500 mg Q3W, followed by maintenance Imfinzi 1,500 mg Q4W until disease progression or unacceptable toxicity. Patients in the EP arm received up to 6 cycles of EP and optional prophylactic cranial irradiation. Administration of Imfinzi monotherapy was permitted beyond disease progression if the patient was clinically stable and deriving clinical benefit as determined by the investigator (not recommended). In this planned exploratory analysis (data cut-off 22 March 2021), long-term follow-up for the primary endpoint of OS (time from randomization until death from any cause) for Imfinzi + EP vs. EP are reported.3
EP, etoposide and either carboplatin or cisplatin; Q3W, every 3 weeks; Q4W, every 4 weeks.
Nurse Kit Resources
imAR Handbook
High-level details concerning imAEs, how to recognize them, and how to manage them.
imAR Checklist
A concise checklist that allows you to run through potential imARs during your patient consultation.
Pocket Guide
A tool that you can carry with you at all times that provides an overview of imAEs and their management.
GP/Pharmacist ImAR Letter
To give to pharmacists and healthcare professionals in your centre/clinic so they can better understand the patient’s treatment and how to manage their potential side effects.
Patient Side Effects Tracker
Tear Pad
A tool for your patients to track and communicate their side effects in a clear and comprehensive table.
HCP Resources
PACIFIC Trail Paper
Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342-2350.
Reprint of the pivotal PACIFIC trial overall survival results, as published in the New England Journal of Medicine.
PACIFIC Postcard
Overview of the IMFINZI indication and its use in the PACIFIC Regimen.
For Patients
IMFINZI Note Card
A small card for patients to take notes when discussing their IMFINZI treatment plan.
Chemoradiation Therapy Postcard
An overview of the definitive platinum-based concurrent chemoradiation therapy (cCRT) regimens received by patients prior to their enrollment in the PACIFIC Study.
Clinical Efficacy and Dosing Guide
A review of IMFINZI clinical efficacy results from the PACIFIC trial, and recommended dosing and administration with adjustment guidance.
CASPIAN 3-Year Updated OS
Analysis Publication
ES-SCLC
Imfinzi 's 3-year updated OS data in
ES-SCLC patients.
Paz-Ares L, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022; 7(2):100408.
CASPIAN OS Data Summary
ES-SCLC
An overview of the CASPIAN primary and 3-year OS data.
Dosing Guide
ES-SCLC
A guide for Imfinzi’s recommended dosage, dosage adjustments, and administration.
-Handbook-Thumbnail.png)
Immune-Mediated Adverse Reactions (imARs) Handbook
ES-SCLC
A guide for recognizing and managing imARs associated with Imfinzi.
Imfinzi Product Monograph
ES-SCLC
Complete details on Imfinzi’s properties, indications, dosing, contraindications, warnings, adverse events, and clinical pharmacology.
ES-SCLC, extensive-stage small cell lung cancer; HCP, healthcare professional; imARs, immune-mediated adverse reactions; OS, overall survival.
Patient Resources
Patient Information and Side
Effects Brochure
ES-SCLC
A guide for patients with important information
about IMFINZI treatment and how to recognize
possible side effects.
Caregiver Brochure
ES-SCLC
Guidance for Imfinzi patients' loved ones
to help them through the treatment process.
Side Effects Tracker
ES-SCLC
A tool for patients to track any side effects they may experience during treatment.
References:
1. Imfinzi Product Monograph. AstraZeneca Canada Inc. January 17, 2025.
2. Paz-Ares L, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
Lancet. 2019;394(10212):1929-1939.
3. Paz-Ares L, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7(2):100408.
2. Paz-Ares, L., Dvorkin, et al. (2019). Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial.
Lancet.2019;394(10212):1929-1939.
3. Paz-Ares L, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN*. ESMO Open. 2022;7(2):100408.